Early estimates of influenza vaccine effectiveness in Navarre, Spain: 2012/13 mid-season analysis

J Castilla; I Martínez-Baz; V Martínez-Artola; M Fernandez-Alonso; G Reina; M Guevara; M García Cenoz; F Elía; N Alvarez; A Barricarte; C Ezpeleta

doi:10.2807/ese.18.07.20404-en

Rapid communications Open Access

Like 0

Download

Early estimates of influenza vaccine effectiveness in Navarre, Spain: 2012/13 mid-season analysis
J Castilla^1,2 , I Martínez-Baz^1,2 , V Martínez-Artola³ , M Fernandez-Alonso⁴ , G Reina⁴ , M Guevara^1,2 , M García Cenoz^1,2 , F Elía⁵ , N Alvarez⁶ , A Barricarte^1,2 , C Ezpeleta³
View Affiliations Hide Affiliations

Affiliations: ¹ Instituto de Salud Pública de Navarra (Public Health Institute of Navarre), Pamplona, Spain ² Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP; Network of Biomedical Research Centers Epidemiology and Public Health), Spain ³ Complejo Hospitalario de Navarra (Hospital Complex of Navarre), Pamplona, Spain ⁴ Clínica Universidad de Navarra (University Clinic of Navarre), Pamplona, Spain ⁵ Primary Healthcare Directorate, Navarre Health Service, Pamplona, Spain ⁶ Servicio Navarro de Salud (Navarre Health Service), Pamplona, Spain

Correspondence:
J Castilla
jcastilc navarra.es

Correspondence: J Castilla
jcastilc navarra.es
View Citation Hide Citation

Citation style for this article: Castilla J, Martínez-Baz I, Martínez-Artola V, Fernandez-Alonso M, Reina G, Guevara M, García Cenoz M, Elía F, Alvarez N, Barricarte A, Ezpeleta C. Early estimates of influenza vaccine effectiveness in Navarre, Spain: 2012/13 mid-season analysis. Euro Surveill. 2013;18(7):pii=20404. https://doi.org/10.2807/ese.18.07.20404-en Received: 01 Feb 2013

Abstract

We present estimates of influenza vaccine effectiveness (VE) in Navarre, Spain, in the early 2012/13 season, which was dominated by influenza B. In a population-based cohort using electronic records from physicians, the adjusted VE in preventing influenza-like illness was 32% (95% confidence interval (CI): 15 to 46). In a nested test-negative case-control analysis the adjusted VE in preventing laboratory-confirmed influenza was 86% (95% CI: 45 to 96). These results suggest a high protective effect of the vaccine. .